Nuvalent (NUVL) Change in Accured Expenses (2020 - 2026)
Nuvalent (NUVL) reported Change in Accured Expenses of -$2.1 million for Q1 2026, down 471.85% on a YoY basis from $573618.6 in Q1 2025, and up 65.79% quarter-over-quarter from -$6.2 million in Q4 2025.
Nuvalent (NUVL) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Nuvalent has reported Change in Accured Expenses for 7 years, with the latest figure at -$2.1 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 471.85% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.7 million (down 66.02% YoY), and the FY2025 full-year result was $11.5 million, down 57.34% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$2.1 million, up from -$6.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $13.7 million in Q4 2024, with the low at -$6.2 million in Q4 2025.
- Historically, Change in Accured Expenses has averaged $3.0 million across 5 years, with a median of $2.5 million in 2023.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 5382.35% — and 2026, when it plunged 471.85%.
- Nuvalent's Change in Accured Expenses stood at $4.5 million in 2022, then decreased by 14.03% to $3.8 million in 2023, then surged by 257.18% to $13.7 million in 2024, then tumbled by 145.35% to -$6.2 million in 2025, then jumped by 65.79% to -$2.1 million in 2026.
- The last three Change in Accured Expenses figures came in at -$2.1 million (Q1 2026), -$6.2 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -2.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.13 Mn |
| Mar 31, 2026 | -2.13 Mn |
| Dec 31, 2025 | -6.24 Mn |
| Dec 31, 2025 | -6.24 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Jun 30, 2025 | 12.84 Mn |
| Jun 30, 2025 | 12.84 Mn |
| Mar 31, 2025 | -373,000.00 |
| Mar 31, 2025 | -373,000.00 |
| Dec 31, 2024 | 13.75 Mn |
| Dec 31, 2024 | 13.75 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 10.91 Mn |
| Jun 30, 2024 | 10.91 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Dec 31, 2023 | 3.85 Mn |